Prostate Cancer Foundation Denosumab May Prolong Metastasis-Free Survival in Men with High-Risk Prostate Cancer

Published: May 17, 2011

SANTA MONICA, Calif.--(BUSINESS WIRE)--Data on the use of denosumab (Xgeva) to improve bone metastases-free survival in men with high-risk prostate cancer was presented at the American Urological Association conference today for the first time. If approved by the Food and Drug Administration (FDA), the use of denosumab injections will be the first successful treatment for bone metastasis prevention in prostate cancer.

Back to news